Plain English Summary
Background and study aims
Dry eye disease occurs when the eyes do not make enough tears or the tears evaporate too quickly, leading to the eyes drying out and becoming inflamed (red and swollen) and irritated. Our aim is to study the effect of topical administration of TRPM8 agonist in patients with mild to moderate dry eye disease.
Who can participate?
Patients with mild to moderate dry eye.
What does the study involve?
60 patients are randomly allocated to be treated with either TRPM8 agonist dissolved in distilled water, or distilled water only. Study medications will be topically applied twice on the upper eyelid. The severity of dry eye symptoms will be evaluated before and 1 hour after application.
What are the possible benefits and risks of participating?
There are no benefits and risks involved in this study.
Where is the study run from?
Department of Ophthalmology, Chonnam National University Medical School and Hospital (South Korea).
When is the study starting and how long is it expected to run for?
From January 2015 to March 2015.
Who is funding the study?
Investigator initiated and funded (South Korea).
Who is the main contact?
Pf. Kyung Chul Yoon
Prof Kyung Chul Yoon
Department of Ophthalmology
Chonnam National University Medical School and Hospital
Effect of topical administration of TRPM8 agonist in patients with dry eye disease: a single-center randomized double-masked vehicle-controlled study
TRPM8 (transient receptor potential melastatin 8)
Topical administration of TRPM8 agonist may increase basal tear production in patients with mild to moderate dry eye disease. Also, it may provide short-term symptom relief of ocular dryness.
Institutional Review Board of Chonnam National University Hospital, 10/07/2014, IRB No. CNUH 2014-171
Single-center randomized double-masked vehicle-controlled study
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Dry eye is a disorder of the tear film due to tear deficiency or excessive evaporation, which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort.
TRPM8 agonist (1-(Diisopropyl-phosphinoyl)-nonane) dissolved in distilled water (2 mg/mL) or vehicle (distilled water) was topically delivered using the absorbent cotton gauze square (0.4 g rectangle (50 mm x 60 mm), CS-being, Daisan Cotton, Japan) and wiped twice across the closed eyelid. A loading volume of 0.5 mL of solution on cotton was used to wet the cotton.
Primary outcome measures
1. Basal tear secretion (baseline and every 20 minutes) – assessed by Schirmer score
2. Dry eye symptom (baseline and after 60 minutes): using the questionnaire (0, no symptoms; 1, mild symptoms; 2, moderate symptoms; 3, severe symptoms; and 4, very severe symptoms)
Secondary outcome measures
1. Cooling sensation (baseline and every 5 minutes) – assessed by visual analogue scale (VAS) (0 to 10)
2. Tear-film break up time (baseline and every 10 minutes) - the time before the defect of fluorescein dye appeared in the stained tear film was measured and recorded (measured TBUT 3 times and averaged)
3. Corneal sensitivity (baseline and every 20 minutes) – measured using the Cochet-Bonnet esthesiometer
4. Keratoepitheliopathy score (baseline and every 30 minutes) – after staining the cornea with fluorescein dye, the score was obtained by multiplying the stained area (0-3) by stained density (0-3)
Area (0, no punctate staining; 1, area occupied less than 1/3 of the cornea; 2, area occupied 1/3 to 2/3 of the cornea; 3, area occupied greater than 2/3 of the cornea)
Density (0, no punctate staining; 1, sparse density; 2, moderate density; 3, high density and the overlapped lesions)
These outcomes were measured for 1 hour (60 minutes)
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Dry eye symptoms for more than 3 months despite the use of artificial tears
2. Low tear film break-up time (TBUT) (≤ 7 seconds)
3. Low Schirmer score (≤ 10 mm/5 min)
4. Presence of corneal and conjunctival epithelial damage
Target number of participants
60 patients (30 patients in each group)
Participant exclusion criteria
1. History of any ocular disease other than DED
2. Meibomian gland dysfunction
3. Contact lens use
4. Ocular trauma or surgeries
5. Presence of an uncontrolled systemic disease that could affect ocular surface condition
6. Punctual plugs
7. Used any eye drops other than artificial tears
8. Used any systemic medication that can cause dry eye
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Department of Ophthalmology, Chonnam National University Medical School and Hospital
42 Jebong-ro Dong-gu
Investigator initiated and funded (South Korea)
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
To be confirmed at a later date
Intention to publish date
Participant level data
Results - basic reporting